🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

265 results for “LG” Clear

  1. XPF-002

    Xenon Pharmaceuticals

    Primary Erythromelalgia

    phase 2 small molecule completed

    1 trial

  2. XPF-005

    Xenon Pharmaceuticals

    Acne Vulgaris

    phase 2 small molecule completed

    1 trial

  3. Xyrem (sodium oxybate) oral solution

    Jazz Pharmaceuticals Ireland Limited

    Fibromyalgia

    phase 2 small molecule completed

    1 trial

  4. ZENGAC “500 mg Polvere per soluzione per infusione e per uso orale”, Plenvu, polvere per soluzione orale, SELG ESSE polvere per soluzione orale, Avastin 25 mg/ml concentrate for solution for infusion., Tecentriq 1 200 mg concentrate for solution for infusion, Vancomicina Mylan 500 mg polvere per soluzione per infusione

    Istituto Gentili S.r.l.

    unresectable hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  5. ZG005

    Suzhou Zelgen Biopharmaceuticals Co.,Ltd

    Biliary Tract Carcinoma

    phase 2 small molecule active

    1 trial

  6. [68Ga]FAPI-46

    Disc Medicine

    giant cell arteritis - polymyalgia rheumatica spectrum disease

    phase 2 small molecule active

    1 trial

  7. filgrastim

    Ultragenyx UK Limited

    Shwachman Syndrome

    phase 2 small molecule completed

    1 trial

  8. idecabtagene vicleucel

    Celgene Europe Limited

    Relapsed and refractory multiple myeloma (RRMM), multiple myeloma (MM) with progression within 18 months of initial treatment/ or newly diagnosed multiple myeloma (NDMM) with suboptimal response post autologous stem cell transplant (ASCT) (Cohort 3 only)

    phase 2 small molecule active

    1 trial

  9. scAAV9/AGA

    Ultragenyx UK Limited

    Aspartylglucosaminuria

    phase 2 gene therapy active

    1 trial

  10. tbo-filgrastim

    Teva Pharma GmbH

    Neutropenia

    phase 2 small molecule completed

    1 trial

  11. A Phase 1 Study of BMS-986453 in Participants with Relapsed and/or Refractory Multiple Myeloma

    Celgene Europe Limited

    Relapsed and/or Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  12. A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with RMS, PMS, or MG(Breakfree-2)

    Celgene Europe Limited

    Myasthenia gravis (MG), Progressive Multiple Sclerosis (PMS), Relapsing Multiple Sclerosis (RMS)

    phase 1 other active

    1 trial

  13. A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with Severe, Refractory Autoimmune Diseases (Breakfree-1)

    Celgene Europe Limited

    Systemic Sclerosis, Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathy, Systemic Lupus Erythematosus (SLE)

    phase 1 other active

    1 trial

  14. A clinical study to test the safety (any good or bad effects) of CC-90011 in combination with standard of care (cisplatin and etoposide), on how long the drug can stay in the body and if it can control the disease of people diagnosed with extensive small cell lung cancer and have not had any previous treatment for the disease. CC-90011, single agent, will be also given in consolidation after completion of the 4 to 6 cycles of chemotherapy

    Celgene Europe Limited

    extensive stage small cell lung cancer

    phase 1 other active

    1 trial

  15. A study to assess the effect of CC-95251 alone and in combination with anti-cancer drugs in subjects with Acute Myeloid Leukemia and Myelodysplastic Syndromes

    Celgene Europe Limited

    Acute Myeloid Leukemia and Myelodysplastic Syndromes

    phase 1 other active

    1 trial

  16. A trial of prednisolone in combination with SPI-62 in participants with polymyalgia rheumatica (PMR)

    Lacuna Pharma Pty Ltd

    polymyalgia rheumatica

    phase 1 other active

    1 trial

  17. ALG-000184

    Aligos Therapeutics

    Chronic Hepatitis B

    phase 1 small molecule completed

    1 trial

  18. ALG-010133

    Aligos Therapeutics

    Chronic Hepatitis B

    phase 1 small molecule terminated

    1 trial

  19. ALG-020572

    Aligos Therapeutics

    Chronic Hepatitis B

    phase 1 small molecule terminated

    1 trial

  20. ALG-055009

    Aligos Therapeutics

    Healthy Volunteer Study

    phase 1 small molecule completed

    1 trial

  21. ALG-055009

    Aligos Therapeutics

    NASH - Nonalcoholic Steatohepatitis

    phase 1 small molecule completed

    1 trial

  22. ALG-097558

    Aligos Therapeutics

    COVID-19

    phase 1 small molecule completed

    3 trials

  23. ALG-125755

    Aligos Therapeutics

    Chronic Hepatitis B

    phase 1 small molecule terminated

    1 trial

  24. Adapalene

    Teva Pharma GmbH

    Acne Vulgaris

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources